Changes in the expression of AP-1 components are recorded in various malignant neoplasms, in particular, in samples of patients with breast carcinoma, gynecological cancers, gastrointestinal carcinomas, and hematological malignancies (in chronic myelogenous leukemia and acute myeloid leukemia, Hodgkin’s lymphoma and anaplastic large cell lymphoma) [164]. Here, FOS is linked to chronic myelogenous leukemia, BCR-ABL1 positive.